PCI Pharma Services, a leading contract development and manufacturing organization, has won two awards in the 2024 Pharmaceutical Technology Excellence Awards for its innovation in supply chain management and significant business expansion in the injectable drug delivery segment.
The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the pharmaceutical industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies that are driving change in the industry.
PCI Pharma Services won the Innovation award for its groundbreaking pci | bridgeTM platform, which provides real-time supply chain visibility and automates complex processes in clinical trials and commercial product management. The company secured the Business Expansion award due to its substantial investments in the injectable drug delivery sector, including the development of new state-of-the-art facilities to enhance sterile fill-finish production together with the final assembly, testing and packaging capabilities, and capacities for advanced drug delivery/drug-device combination products. globally.
Real-time supply chain management with pci | bridgeTM
PCI Pharma Services has set a new standard in supply chain management with its pioneering digital platform, pci | bridgeTM. This innovative tool provides unparalleled real-time visibility across inventory, production, and distribution, revolutionizing the way clinical trials and commercial product lifespans are managed. Unlike traditional systems that offer delayed data updates, pci | bridgeTM aggregates real-time information, empowering users with instant access to critical data and insights.
The platform’s user-centric design is evident in its continuous evolution, driven by client feedback. By integrating with digital tools such as DocuSign and Smartsheet, pci | bridgeTM enhances user experience and streamlines project management processes. This integration ensures seamless document sharing and project timeline tracking, keeping projects on course and reducing manual intervention. Supporting over 5,000 clinical and commercial products, pci | bridgeTM connects more than 450 clients and 1,350 unique users monthly, demonstrating its robust capabilities and widespread adoption.
Furthermore, pci | bridgeTM is designed to be highly customizable, allowing users to tailor dashboards and reports to their specific needs. This flexibility is crucial in the pharmaceutical industry, where different projects may require unique data sets and reporting formats. The platform’s ability to provide real-time alerts and notifications further enhances its utility, enabling users to respond swiftly to changes in supply chain dynamics. PCI’s commitment to continuous improvement is underscored by its planned $1.2 million investment in new platform enhancements, which will include expanded visibility into the product lot release life cycle, a new demand planning and forecasting submission interface, the introduction of electronic forms, and other digitized solutions.
Strategic expansion in injectable drug delivery
PCI Pharma Services’ strategic investments in the injectable drug delivery sector have positioned the company as a leader in this rapidly growing market. With a commitment of $465 million, PCI is expanding its capabilities to meet the increasing demand for injectable solutions. A significant portion of this investment, $100 million, is dedicated to a new sterile fill-finish facility in Bedford, New Hampshire, which will be operational by Q1 2025.
This state-of-the-art facility will feature Annex 1 compliant technologies, including an isolator contained aseptic vial filling line and twin lyophilizers, providing high-volume production of batch sizes up to 300,000 vials, together with the highest level of sterility assurance. The sterile drug product filling technology’s design minimizes product loss and enhances efficiency, supporting the production of life-changing drugs such as monoclonal antibodies and peptides. The new technology, designed by groninger and SKAN, incorporates SKANFOG® decontamination technology, which optimizes the sterilization process and reduces the use of vaporized hydrogen peroxide by 80%.
The additional $365 million investment sees PCI expanding its EU and US infrastructure supporting the clinical and commercial scale final assembly, testing and packaging of advanced drug delivery and drug-device combination products. These global investments in device-agnostic technologies and scalable injectable processing capabilities ensure PCI can support the entire lifespan of drug-device combination products, from clinical trials to commercialization. The new facilities in Ireland and Rockford, IL will provide flexible drug-device assembly and packaging of prefilled syringes, needle safety devices, autoinjectors, pens and on-body injectors supported with significant temperature-controlled storage capacity, further strengthening PCI’s ability to meet global demand.
By investing in advanced technologies and infrastructure, PCI is, thus, well-positioned to meet the growing needs of the pharmaceutical industry and continue its mission of delivering life-changing therapies to patients worldwide.
“Our digital and technology innovation continues to focus on accelerating the delivering life-changing therapies to our patients. We partner with our clients to understand and respond to their evolving requirements and to align our digital and technology investments across supply chain, quality and operations.”
– Wayne Hull, Chief Digital and Technology Officer, PCI Pharma Services
Company Profile
PCI is your world leading CDMO, truly spanning the cycle, connecting development and commercialization, de-risking the supply chain providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market, and opportunities for commercial success.
PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing development needs throughout the product lifecycle.
PCI offers a global network of innovative centers of excellence for the development, manufacturing, packaging, storage, and distribution of life changing therapies. Our specialist contained manufacturing and packaging facilities dedicated to processing highly potent drug products, combined with our renowned lyophilization and sterile manufacturing capabilities are complemented by a global network of packaging facilities delivering a true end-to-end service. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible.
3001 Red Lion Road, Philadelphia, PA 19144, USA
T: +1 215 613 3600
T: +44 1495 711 222
E-mail: talkfuture@pci.com
Links
Website: https://pci.com/
